Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Tekla Capital Management

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 48
Average round size
The average size of a deal this fund participated in
Portfolio companies 40
Rounds per year 1.33
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 18
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

The main office of represented VC is situated in the Boston. The company was established in North America in United States.

We also calculated 1 valuable employee in our database.

The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Tekla Capital Management, startups are often financed by Novartis Venture Fund, Domain Associates, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Sofinnova Investments, Redmile Group. In the next rounds fund is usually obtained by Sofinnova Investments, Life Sciences Partners, Ysios Capital.

The top amount of exits for fund were in 2019. The usual things for fund are deals in the range of 50 - 100 millions dollars. The real fund results show that this VC is 3 percentage points less often commits exit comparing to other companies. The fund is constantly included in less than 2 investment rounds annually. This Tekla Capital Management works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018.

Among the most popular portfolio startups of the fund, we may highlight Afferent Pharmaceuticals, Merus, CuraSen Therapeutics. We can highlight the next thriving fund investment areas, such as Medical, Health Care. The fund has exact preference in a number of founders of portfolio startups. When startup sums 3 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Banca Generali Friuli-Venezia Giulia, Italy, Trieste Berlin, Berlin, Germany
Catella Healthcare Investments Stockholm, Stockholm County, Sweden
ECentury Capital Partners Mclean, United States, Virginia
FABERNOVEL France, Ile-de-France, Paris
Goldfinch Partners Seattle, United States, Washington
imToken Central, Central Region, Singapore
Ingenium Catania Fund -
Jacobs Dallas, Texas, United States
MultiPlan New York, New York, United States
Orange Wings Capital -
Prokom Investments Gdynia, Poland, Pomorskie
SARVA India, Maharashtra, Mumbai
Sunny Giken Hyogo Prefecture, Itami, Japan
Tangent Fund Management -
Wefunder California, San Francisco, United States
Zaoniao Jijin -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$60M10 May 2022 Boston, Massachusetts, United States

MoonLake Immunotherapeutics

$115M06 Apr 2022 Zug, Zug, Switzerland

Arkuda Therapeutics

Health Care
$64M10 Feb 2022 Cambridge, Massachusetts, United States

Endeavor BioMedicines

$101M07 Feb 2022 California, United States

Quell Therapeutics

$156M29 Nov 2021 London, England, United Kingdom

Arbor Biotechnologies

Life Science
$215M09 Nov 2021 Cambridge, Massachusetts, United States

Parthenon Therapeutics

Life Science
$65M03 Nov 2021 Cambridge, Massachusetts, United States

ReCode Therapeutics

Health Care
$80M21 Oct 2021 Dallas, Texas, United States

Aristea Therapeutics

$63M27 Jul 2021 San Diego, California, United States
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Aristea Therapeutics Closes $63M Series B Financing

– Aristea Therapeutics, a San Diego, CA-based clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, closed a $63m Series B financing.
– The round was led by Fidelity Management & Research Company, with participation from existing investor Novo Holdings A/S and new investors Arena Pharmaceuticals and funds managed by Tekla Capital Management.
– The company intends to use the funds to continue the build-out of its leadership team, the formation of new partnerships and the advancement of the development of its portfolio of immunology focused programs to address orphan diseases.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Tekla Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: